Nifty
Sensex
:
:
11521.05
38386.75
-11.35 (-0.10%)
23.28 (0.06%)

Pharmaceuticals & Drugs

Rating :
71/99

BSE: 524804 | NSE: AUROPHARMA

776.60
-0.75 (-0.10%)
20-Mar-2019 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  779.90
  •  786.50
  •  775.00
  •  777.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1306974
  •  10149.96
  •  830.45
  •  527.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 45,563.11
  • 19.74
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,071.43
  • 0.32%
  • 3.33

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.87%
  • 3.24%
  • 9.07%
  • FII
  • DII
  • Others
  • 0.06%
  • 14.38%
  • 21.38%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.26
  • 15.24
  • 6.07

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 30.30
  • 12.07
  • 3.42

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 47.02
  • 15.59
  • 6.14

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.89
  • 19.01
  • 18.23

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.02
  • 5.25
  • 4.29

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.90
  • 13.21
  • 12.38

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
5,269.67
4,336.11
21.53%
4,751.40
4,435.89
7.11%
4,250.27
3,678.75
15.54%
4,049.09
3,641.63
11.19%
Expenses
4,183.29
3,310.53
26.36%
3,765.13
3,319.01
13.44%
3,539.21
2,844.81
24.41%
3,260.98
2,920.39
11.66%
EBITDA
1,086.38
1,025.58
5.93%
986.27
1,116.88
-11.69%
711.06
833.94
-14.73%
788.11
721.24
9.27%
EBIDTM
20.62%
23.65%
20.76%
25.18%
16.73%
22.67%
19.46%
19.81%
Other Income
63.85
33.05
93.19%
26.26
10.27
155.70%
43.73
22.09
97.96%
43.83
40.78
7.48%
Interest
47.65
18.86
152.65%
35.39
17.27
104.92%
29.54
16.87
75.10%
24.72
14.28
73.11%
Depreciation
163.12
138.08
18.13%
163.68
132.08
23.92%
154.53
131.18
17.80%
156.63
100.05
56.55%
PBT
914.42
901.69
1.41%
786.62
977.80
-19.55%
570.72
707.98
-19.39%
650.59
647.69
0.45%
Tax
204.78
306.94
-33.28%
175.42
197.96
-11.39%
115.54
190.99
-39.50%
122.39
117.15
4.47%
PAT
709.64
594.75
19.32%
611.20
779.84
-21.62%
455.18
516.99
-11.96%
528.20
530.54
-0.44%
PATM
13.47%
13.72%
12.86%
17.58%
10.71%
14.05%
13.04%
14.57%
EPS
12.16
10.16
19.69%
10.44
13.33
-21.68%
7.78
8.85
-12.09%
9.02
9.09
-0.77%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
18,320.43
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
4,381.48
3,575.44
3,077.28
Net Sales Growth
13.85%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
5.61%
22.54%
16.19%
 
Cost Of Goods Sold
8,009.49
6,162.23
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
1,963.83
1,574.54
1,533.07
Gross Profit
10,310.94
10,300.80
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
2,417.65
2,000.90
1,544.21
GP Margin
56.28%
62.57%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
55.18%
55.96%
50.18%
Total Expenditure
14,748.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
3,418.22
2,752.25
2,809.89
Power & Fuel Cost
-
470.95
437.14
419.26
359.60
349.84
324.72
232.36
208.26
194.91
182.72
% Of Sales
-
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
4.75%
5.45%
5.94%
Employee Cost
-
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
425.07
324.13
240.89
% Of Sales
-
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
9.70%
9.07%
7.83%
Manufacturing Exp.
-
1,534.44
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
511.60
349.01
268.67
% Of Sales
-
9.32%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
11.68%
9.76%
8.73%
General & Admin Exp.
-
1,068.21
997.32
686.38
666.38
283.49
197.83
130.74
120.34
116.94
104.63
% Of Sales
-
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
2.75%
3.27%
3.40%
Selling & Distn. Exp.
-
1,025.85
848.43
901.87
878.98
359.60
305.98
208.20
141.59
143.56
152.87
% Of Sales
-
6.23%
5.69%
6.54%
7.25%
4.44%
5.23%
4.50%
3.23%
4.02%
4.97%
Miscellaneous Exp.
-
298.76
203.97
187.92
227.09
123.20
149.49
111.96
47.53
49.16
152.87
% Of Sales
-
1.81%
1.37%
1.36%
1.87%
1.52%
2.55%
2.42%
1.08%
1.37%
10.63%
EBITDA
3,571.82
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
963.26
823.19
267.39
EBITDA Margin
19.50%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
21.98%
23.02%
8.69%
Other Income
177.67
101.98
115.89
203.80
96.71
21.56
28.54
24.70
71.41
151.49
26.05
Interest
137.30
77.72
66.72
256.70
159.87
310.16
266.64
277.24
64.65
73.09
93.22
Depreciation
637.96
557.97
427.63
392.37
332.61
312.53
248.74
200.53
171.50
149.34
127.60
PBT
2,922.35
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
798.52
752.25
72.62
Tax
618.13
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
225.12
191.36
21.36
Tax Rate
21.15%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
28.56%
25.44%
29.41%
PAT
2,304.22
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
563.45
561.21
51.31
PAT before Minority Interest
2,304.04
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
563.06
560.89
51.26
Minority Interest
-0.18
0.26
0.47
1.50
4.51
3.78
2.46
0.64
0.39
0.32
0.05
PAT Margin
12.58%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
12.86%
15.70%
1.67%
PAT Growth
-4.87%
5.37%
13.49%
28.42%
34.35%
299.12%
-
-
0.40%
993.76%
 
Unadjusted EPS
39.40
41.36
39.33
34.67
27.03
40.27
10.09
-4.24
19.57
20.81
18.65

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
2,444.83
1,829.08
1,241.26
Share Capital
58.59
58.59
58.52
29.20
29.15
29.12
29.11
29.11
27.86
26.88
Total Reserves
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
2,415.72
1,801.22
1,214.38
Non-Current Liabilities
583.54
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
645.49
2,245.74
2,409.84
Secured Loans
26.96
177.59
380.10
773.54
1,101.31
1,084.11
862.08
449.74
864.05
987.67
Unsecured Loans
424.24
3.81
362.71
587.93
178.05
64.15
102.55
73.61
1,290.51
1,345.30
Long Term Provisions
55.86
39.13
23.36
24.35
9.18
9.00
4.24
3.09
0.00
0.00
Current Liabilities
8,680.62
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
2,768.49
707.99
570.05
Trade Payables
2,627.44
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
776.35
604.40
514.77
Other Current Liabilities
1,777.80
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
699.09
68.40
28.69
Short Term Borrowings
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
1,234.73
0.00
0.00
Short Term Provisions
244.04
261.36
132.93
218.24
126.60
80.09
66.36
58.32
35.19
26.59
Total Liabilities
20,946.40
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14
4,224.30
Net Block
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
1,738.60
1,710.85
1,398.77
Gross Block
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
2,438.00
2,407.67
1,973.63
Accumulated Depreciation
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
699.40
696.82
574.86
Non Current Assets
8,758.56
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
2,546.75
2,280.47
1,934.61
Capital Work in Progress
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
582.86
570.08
536.30
Non Current Investment
311.52
245.85
122.94
0.14
19.76
22.24
19.86
38.49
-0.46
-0.46
Long Term Loans & Adv.
255.76
256.48
236.56
455.27
789.04
237.82
108.12
110.77
0.00
0.00
Other Non Current Assets
87.56
81.29
32.24
30.25
18.40
18.66
0.12
1.47
0.00
0.00
Current Assets
12,187.84
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
3,321.18
2,506.67
2,289.69
Current Investments
0.02
0.02
0.02
19.65
0.03
0.04
18.68
0.04
0.74
0.72
Inventories
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
1,455.27
1,102.45
877.63
Sundry Debtors
3,084.36
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
1,230.98
956.01
889.76
Cash & Bank
1,261.62
513.48
800.26
469.11
178.58
208.45
70.86
186.72
72.83
127.65
Other Current Assets
1,983.43
1,084.72
464.37
271.67
448.46
407.69
388.98
448.17
374.64
393.93
Short Term Loans & Adv.
760.11
512.09
366.88
387.90
237.22
207.51
216.67
358.87
280.60
333.16
Net Current Assets
3,507.22
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
552.69
1,798.68
1,719.64
Total Assets
20,946.40
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
4,787.14
4,224.30

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,954.82
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
335.11
425.18
136.03
PBT
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
798.52
752.25
72.62
Adjustment
535.02
408.92
487.50
406.28
515.12
441.54
387.22
197.72
99.77
427.84
Changes in Working Capital
-1,068.98
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
-469.45
-273.72
-334.21
Cash after chg. in Working capital
2,707.22
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
526.79
578.30
166.25
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-752.40
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
-191.68
-153.12
-30.22
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,956.95
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
-599.07
-399.02
-406.28
Net Fixed Assets
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
-396.28
-478.66
-288.52
Net Investments
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
-122.17
-101.50
18.54
Others
-900.40
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
-80.62
181.14
-136.30
Cash from Financing Activity
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
406.98
-84.04
164.99
Net Cash Inflow / Outflow
862.02
-423.72
339.99
-67.95
-54.82
136.62
-118.06
143.02
-57.88
-105.26
Opening Cash & Equivalents
319.63
743.49
403.81
148.02
202.73
65.64
183.71
44.72
102.65
235.68
Closing Cash & Equivalent
1,211.84
319.63
743.50
461.10
148.02
202.73
65.64
183.71
47.19
96.96

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
199.36
159.96
124.50
88.29
64.33
44.74
40.19
41.99
32.83
23.09
ROA
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
10.57%
12.45%
1.30%
ROE
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
26.35%
36.54%
4.33%
ROCE
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
19.29%
21.84%
5.07%
Fixed Asset Turnover
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
1.67
1.72
Receivable days
64.70
89.16
106.53
91.84
93.55
86.28
95.44
89.07
92.25
89.57
Inventory Days
112.70
101.43
100.27
88.91
94.82
105.51
115.91
104.17
98.97
96.37
Payable days
71.58
75.73
81.50
67.49
71.06
57.79
64.70
70.79
72.18
71.28
Cash Conversion Cycle
105.81
114.86
125.30
113.25
117.31
134.00
146.65
122.45
119.04
114.66
Total Debt/Equity
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
1.18
1.88
Interest Cover
42.66
46.80
11.69
14.56
5.94
2.40
0.23
13.19
11.29
1.78

News Update:


  • Aurobindo Pharma’s arm completes acquisition of marketed portfolio from Spectrum Pharma
    2nd Mar 2019, 12:31 PM

    The acquisition has been completed on March 1, 2019

    Read More
  • Aurobindo Pharma completes acquisition of Apotex’s Businesses in five European countries
    11th Feb 2019, 09:20 AM

    The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products

    Read More
  • Aurobindo Pharma reports 20% rise in Q3 consolidated net profit
    8th Feb 2019, 10:08 AM

    Total consolidated income of the company increased by 22.07% at Rs 5,333.52 crore for Q3FY19

    Read More
  • Aurobindo Pharma to invest Rs 15 crore in Synergy Remedies
    8th Feb 2019, 09:06 AM

    After making the said investment, the Company will be holding 19.9% of the share capital of Synergy

    Read More
  • Aurobindo Pharma - Quarterly Results
    7th Feb 2019, 20:06 PM

    Read More
  • Aurobindo recalling nearly 5 lakh bottles of blood pressure drug in US
    28th Jan 2019, 10:57 AM

    The American health regulator found certain deviations from Current Good Manufacturing Practice regulations

    Read More
  • Aurobindo Pharma’s arm to acquire portfolio of seven marketed oncology injectable products
    18th Jan 2019, 09:01 AM

    The acquisition will provide new opportunities to grow the business by launching innovative branded products in oncology

    Read More
  • Aurobindo Pharma’s arm recalls 80 lots of blood pressure drug from America
    2nd Jan 2019, 10:13 AM

    This is done due to presence of impurity found in the finished drug product that may cause cancer in humans

    Read More
  • Aurobindo Pharma’s injectable business achieves $50 million revenue in Q2
    27th Dec 2018, 14:59 PM

    The company has filed a total of 104 injectables, abbreviated new drug applications (ANDAs), out of which 59 have received final approval and one tentative approval

    Read More
  • Aurobindo Pharma receives USFDA nod for Vecuronium Bromide Injection
    24th Dec 2018, 10:16 AM

    Vecuronium Bromide Injection is used as part of general anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation

    Read More
  • Aurobindo Pharma receives USFDA’s nod for Potassium Chloride ER Tablets
    21st Dec 2018, 14:04 PM

    Potassium Chloride Extended-Release tablets, a generic version of Upsher-Smith’s Klor-Con Extended Release tablets

    Read More
  • Aurobindo Pharma’s arm enters into agreement with Luoxin
    11th Dec 2018, 15:38 PM

    The agreement aims to establish a JV company in China with manufacturing facilities to manufacture nebuliser inhaler

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.